Carregant...
Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
IMPORTANCE: Although PCSK9 inhibitors (PCSK9i) were approved in 2015, their high cost has led to strict prior authorization practices and high copays, and use of PSCK9i in clinical practice has been low. OBJECTIVE: To evaluate patient access to PCSK9i among those prescribed therapy. DESIGN, SETTING,...
Guardat en:
| Publicat a: | JAMA Cardiol |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Medical Association
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5963012/ https://ncbi.nlm.nih.gov/pubmed/28973087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3451 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|